Effects of Acute Caffeine Intake on Insulin-Like Growth Factor-1 Responses to Total Sleep Deprivation: Interactions with COMT Polymorphism - A Randomized, Crossover Study

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3.

This study aimed to determine the kinetics of IGF-1, testosterone, and cortisol concentrations during prolonged wakefulness under caffeine or placebo intake in 37 healthy participants, and to analyze whether the responses are dependent on COMT rs4680 or ADORA2A rs5751876 SNPs.

Why It Was Studied

The rs4680 single-nucleotide polymorphism (SNP) of COMT differentiates on memory score and circulating levels of the neurotrophic factor IGF-1.

Who Took Part

According to the abstract, 37 participants were involved.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and crossover study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

Each person switched between IGF-1 LR3 and the comparison at some point, usually with a gap in between.

Genotyping was performed on blood cells.

What Was Measured

The rs4680 single-nucleotide polymorphism (SNP) of COMT differentiates on memory score and circulating levels of the neurotrophic factor IGF-1.

The subject headings attached to it are Sleep Deprivation, Caffeine, Insulin-Like Peptides, Transferases, Insulin-Like Growth Factor I, Hydrocortisone and Polymorphism, Single Nucleotide.

Author keywords: Genetics, Hormones and Total sleep deprivation.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of IGF-1 LR3 in 37 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Lifestyle genomics), a journal based in Switzerland.

More context: the IGF-1 LR3 compound page, all human trials.